Levofloxacin
- PDF / 484,046 Bytes
- 34 Pages / 504.57 x 720 pts Page_size
- 96 Downloads / 143 Views
Drugs 2003; 63 (24): 2769-2802 0012-6667/03/0024-2769/$33.00/0 © Adis Data Information BV 2003. All rights reserved.
Levofloxacin A Review of its Use in the Treatment of Bacterial Infections in the United States Katherine F. Croom and Karen L. Goa Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: J.M. Blondeau, Department of Clinical Microbiology, Royal University Hospital, Saskatoon, Saskatchewan, Canada; D.N. Fish, Department of Pharmacy Practice, Colorado Health Sciences Center, Denver, Colorado, USA; D.R.P. Guay, Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA; M.P. Habib, Pulmonary Section, Veterans Affairs Medical Center, Tucson, Arizona, USA; P.B. Iannini, Department of Medicine, Danbury Hospital, Danbury, Connecticut, USA; S.L. Preston, Clinical Pharmacology Studies Unit, Albany Medical College, Albany, New York, USA; J.A. Ramirez, Department of Medicine, University of Louisville, Louisville, Kentucky, USA; K.A. Rodvold, Department of Pharmacy Practice, University of Illinois, Chicago, Illinois, USA. Data Selection Sources: Medical literature published in any language since 1998 on levofloxacin, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: Medline search terms were ‘levofloxacin’. EMBASE search terms were ‘levofloxacin’ or ‘DR 3355’. AdisBase search terms were ‘levofloxacin’ or ‘DR-3355’. Searches were last updated 10 November 2003. Selection: Studies in patients with bacterial infections who received levofloxacin. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included. Index terms: Acute exacerbations of chronic bronchitis, acute sinusitis, antibacterials, chronic bacterial prostatitis, community-acquired pneumonia, genitourinary tract infections, levofloxacin, nosocomial pneumonia, pharmacodynamics, pharmacokinetics, respiratory tract infections, skin and skin structure infections, therapeutic use, urinary tract infections.
Contents Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2770 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2775 2. Pharmacodynamic Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2775 2.1 In Vitro Activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Data Loading...
